{
    "root": "e7414f2d-d7cf-41e5-b457-f5850e8bb7a7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rizatriptan Benzoate",
    "value": "20250201",
    "ingredients": [
        {
            "name": "RIZATRIPTAN BENZOATE",
            "code": "WR978S7QHH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8875"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        }
    ],
    "indications": {
        "text": "rizatriptan benzoate tablets indicated acute treatment migraine without aura adults pediatric patients 6 17 years old . limitations \u2022 rizatriptan benzoate tablets used clear diagnosis migraine established . patient response first migraine attack treated rizatriptan benzoate tablets , diagnosis migraine reconsidered rizatriptan benzoate tablets administered treat subsequent attacks . \u2022rizatriptan benzoate tablets indicated management hemiplegic basilar migraine [ ( 4 ) ] . \u2022rizatriptan benzoate tablets indicated prevention migraine attacks . \u2022safety effectiveness rizatriptan benzoate tablets established cluster headache .",
        "doid_entities": [
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            },
            {
                "text": "migraine without aura (DOID:12783)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12783"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 adults : 5 mg 10 mg single dose ; separate repeat doses least two hours ; maximum dose 24-hour period : 30 mg ( 2.1 ) \u2022 pediatric patients 6 17 years : 5 mg single dose patients less 40 kg ( 88 lb ) ; 10 mg single dose patients 40 kg ( 88 lb ) ( 2.2 ) \u2022 adjust dose co-administered propranolol ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "rizatriptan benzoate tablets usp , 10 mg pale pink-colored , circular , flat , beveled-edge uncoated tablets debossed \u2018 x \u2019 one side \u2018 14 \u2019 side . tablets may mottled . 12 ( 4 x 3 ) unit-dose tablets ndc 82804-202-12 storage store rizatriptan benzoate tablets usp 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "rizatriptan benzoate tablets contraindicated patients : \u2022 ischemic coronary artery disease ( angina pectoris , history myocardial infarction , documented silent ischemia ) , significant underlying cardiovascular disease [ ( 5.1 ) ] . \u2022coronary artery vasospasm including prinzmetal 's angina [ ( 5.1 ) ] . \u2022history stroke transient ischemic attack ( tia ) [ ( 5.4 ) ] . \u2022peripheral vascular disease ( pvd ) [ ( 5.5 ) ] . \u2022ischemic bowel disease [ ( 5.5 ) ] . \u2022uncontrolled hypertension [ ( 5.8 ) ] . \u2022recent ( i.e . , within 24 hours ) another 5-ht1 agonist , ergotamine-containing medication , ergot-type medication ( dihydroergotamine methysergide ) [ ( 7.2 7.3 ) ] . \u2022hemiplegic basilar migraine [ usage ( 1 ) ] . \u2022concurrent recent discontinuation ( i.e . , within 2 weeks ) mao-a inhibitor [ ( 7.5 ) pharmacology ( 12.3 ) ] . \u2022hypersensitivity rizatriptan excipients ( angioedema anaphylaxis seen ) [ ( 6.2 ) ] .",
    "indications_original": "Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.\n                  \n                     Limitations of Use\n                  \n                  \n                     \n                        \u2022\n                        Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks.\n                     \n                     \n                        \u2022Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)]. \n                     \n                        \u2022Rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks. \n                     \n                        \u2022Safety and effectiveness of rizatriptan benzoate tablets have not been established for cluster headache.",
    "contraindications_original": "\u2022 Adults: 5 mg\u00a0or 10 mg single dose; separate repeat doses by at least two hours; maximum dose in a 24-hour period: 30 mg (2.1) \u2022 Pediatric patients 6 to 17 years: 5 mg single dose in patients less than 40 kg (88 lb); 10 mg single dose in patients 40 kg (88 lb) or more\u00a0( 2.2 ) \u2022 Adjust dose if co-administered with propranolol (2.4)",
    "warningsAndPrecautions_original": "Rizatriptan Benzoate Tablets USP, 10 mg are a pale pink-colored, circular, flat, beveled-edge uncoated tablets debossed with \u2018X\u2019 on one side and \u201814\u2019 on other side. The tablets may be mottled.\n                      \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a012 (4 x 3) Unit-dose Tablets\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 82804-202-12\n                     \n                     \n                     \n                        Storage\n                     \n                     \n                     \n                      Store rizatriptan benzoate tablets USP\u00a0at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Rizatriptan benzoate tablets are contraindicated in patients with:\n                  \n                     \n                        \u2022\n                        Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see Warnings and Precautions (5.1)].\n                     \n                     \n                        \u2022Coronary artery vasospasm including Prinzmetal's angina [see Warnings and Precautions (5.1)].\n                     \n                        \u2022History of stroke or transient ischemic attack (TIA) [see \n                           Warnings and Precautions (5.4)].\n                     \n                        \u2022Peripheral vascular disease (PVD) [see Warnings and Precautions (5.5)].\n                     \n                        \u2022Ischemic bowel disease [see Warnings and Precautions (5.5)].\n                     \n                        \u2022Uncontrolled hypertension [see Warnings and Precautions (5.8)].\n                     \n                        \u2022Recent use (i.e., within 24 hours) of another 5-HT1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.2 and 7.3)]. \n                     \n                        \u2022Hemiplegic or basilar migraine [see Indications and Usage (1)].\n                     \n                     \n                        \u2022Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor [see Drug Interactions (7.5) and Clinical Pharmacology (12.3)].\n                     \n                        \u2022Hypersensitivity to rizatriptan or any of the excipients (angioedema and anaphylaxis seen) [see Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Rizatriptan Benzoate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8875"
        }
    ]
}